WO2001019977A9 - Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions - Google Patents
Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditionsInfo
- Publication number
- WO2001019977A9 WO2001019977A9 PCT/US2000/025090 US0025090W WO0119977A9 WO 2001019977 A9 WO2001019977 A9 WO 2001019977A9 US 0025090 W US0025090 W US 0025090W WO 0119977 A9 WO0119977 A9 WO 0119977A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- cell
- embryonic
- stem
- human
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 144
- 238000010449 nuclear transplantation Methods 0.000 title description 14
- 230000013020 embryo development Effects 0.000 title description 10
- 230000002708 enhancing effect Effects 0.000 title description 9
- 230000004077 genetic alteration Effects 0.000 title description 2
- 231100000118 genetic alteration Toxicity 0.000 title description 2
- 210000004027 cell Anatomy 0.000 claims abstract description 527
- 210000000287 oocyte Anatomy 0.000 claims abstract description 159
- 238000012546 transfer Methods 0.000 claims abstract description 114
- 241000282414 Homo sapiens Species 0.000 claims abstract description 111
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 82
- 238000002054 transplantation Methods 0.000 claims abstract description 26
- 230000006907 apoptotic process Effects 0.000 claims abstract description 23
- 238000011161 development Methods 0.000 claims abstract description 22
- 238000000338 in vitro Methods 0.000 claims abstract description 20
- 210000003855 cell nucleus Anatomy 0.000 claims abstract description 6
- 230000006801 homologous recombination Effects 0.000 claims abstract description 3
- 238000002744 homologous recombination Methods 0.000 claims abstract description 3
- 241000283690 Bos taurus Species 0.000 claims description 74
- 210000005260 human cell Anatomy 0.000 claims description 55
- 241001465754 Metazoa Species 0.000 claims description 40
- 241000288906 Primates Species 0.000 claims description 31
- 210000002950 fibroblast Anatomy 0.000 claims description 30
- 238000012258 culturing Methods 0.000 claims description 29
- 230000014509 gene expression Effects 0.000 claims description 29
- 108020004414 DNA Proteins 0.000 claims description 28
- 230000004927 fusion Effects 0.000 claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 201000010099 disease Diseases 0.000 claims description 21
- 108050006400 Cyclin Proteins 0.000 claims description 20
- 230000007159 enucleation Effects 0.000 claims description 19
- 102000016736 Cyclin Human genes 0.000 claims description 17
- 230000004069 differentiation Effects 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 15
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 13
- 239000003550 marker Substances 0.000 claims description 13
- 210000003981 ectoderm Anatomy 0.000 claims description 12
- 210000003716 mesoderm Anatomy 0.000 claims description 12
- 210000003061 neural cell Anatomy 0.000 claims description 12
- 210000001082 somatic cell Anatomy 0.000 claims description 12
- 238000002560 therapeutic procedure Methods 0.000 claims description 12
- 210000001900 endoderm Anatomy 0.000 claims description 11
- 210000002919 epithelial cell Anatomy 0.000 claims description 10
- -1 Ks-Bcl-2 Proteins 0.000 claims description 9
- 230000006378 damage Effects 0.000 claims description 9
- 239000003112 inhibitor Substances 0.000 claims description 9
- 210000002510 keratinocyte Anatomy 0.000 claims description 9
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 210000004962 mammalian cell Anatomy 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 239000003102 growth factor Substances 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 208000030507 AIDS Diseases 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 210000004698 lymphocyte Anatomy 0.000 claims description 4
- 210000000663 muscle cell Anatomy 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 241000283073 Equus caballus Species 0.000 claims description 3
- 101000743586 Mus musculus Vacuolar protein sorting-associated protein 26A Proteins 0.000 claims description 3
- 241000283984 Rodentia Species 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 210000000845 cartilage Anatomy 0.000 claims description 3
- 210000003321 cartilage cell Anatomy 0.000 claims description 3
- 230000007547 defect Effects 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 208000019622 heart disease Diseases 0.000 claims description 3
- 210000005229 liver cell Anatomy 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 201000006938 muscular dystrophy Diseases 0.000 claims description 3
- 210000002784 stomach Anatomy 0.000 claims description 3
- 230000002485 urinary effect Effects 0.000 claims description 3
- 208000019553 vascular disease Diseases 0.000 claims description 3
- 102100030088 ATP-dependent RNA helicase A Human genes 0.000 claims description 2
- 101710164022 ATP-dependent RNA helicase A Proteins 0.000 claims description 2
- 101100216424 African swine fever virus (strain E-70 MS44) LMW5-HL gene Proteins 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 101100011368 Caenorhabditis elegans egl-1 gene Proteins 0.000 claims description 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- 101710175001 E1B protein, small T-antigen Proteins 0.000 claims description 2
- 208000003790 Foot Ulcer Diseases 0.000 claims description 2
- 101000854890 Haemophilus phage HP1 (strain HP1c1) Probable terminase, ATPase subunit Proteins 0.000 claims description 2
- 101000768945 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 7.9 kDa protein in int-C1 intergenic region Proteins 0.000 claims description 2
- 101150068639 Hnf4a gene Proteins 0.000 claims description 2
- 101000578717 Klebsiella pneumoniae Mannose-1-phosphate guanylyltransferase Proteins 0.000 claims description 2
- 101100013973 Mus musculus Gata4 gene Proteins 0.000 claims description 2
- 208000026723 Urinary tract disease Diseases 0.000 claims description 2
- 208000012931 Urologic disease Diseases 0.000 claims description 2
- 101150039936 ced-9 gene Proteins 0.000 claims description 2
- 102000006495 integrins Human genes 0.000 claims description 2
- 108010044426 integrins Proteins 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 208000014001 urinary system disease Diseases 0.000 claims description 2
- 241000282465 Canis Species 0.000 claims 1
- 241000282324 Felis Species 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 102000055104 bcl-X Human genes 0.000 claims 1
- 108700000711 bcl-X Proteins 0.000 claims 1
- 210000005132 reproductive cell Anatomy 0.000 claims 1
- 210000004927 skin cell Anatomy 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 210000004989 spleen cell Anatomy 0.000 claims 1
- 241000894007 species Species 0.000 abstract description 37
- 238000004519 manufacturing process Methods 0.000 abstract description 33
- 230000018109 developmental process Effects 0.000 abstract description 21
- 210000002308 embryonic cell Anatomy 0.000 abstract description 15
- 210000001671 embryonic stem cell Anatomy 0.000 abstract description 12
- 230000012010 growth Effects 0.000 abstract description 12
- 230000022131 cell cycle Effects 0.000 abstract description 10
- 230000004048 modification Effects 0.000 abstract description 7
- 238000012986 modification Methods 0.000 abstract description 7
- 210000000130 stem cell Anatomy 0.000 abstract description 7
- 230000001976 improved effect Effects 0.000 abstract description 5
- 230000024245 cell differentiation Effects 0.000 abstract description 2
- 210000001519 tissue Anatomy 0.000 description 55
- 210000004940 nucleus Anatomy 0.000 description 52
- 210000002257 embryonic structure Anatomy 0.000 description 45
- 230000004913 activation Effects 0.000 description 35
- 239000001963 growth medium Substances 0.000 description 28
- 210000002459 blastocyst Anatomy 0.000 description 27
- 239000002609 medium Substances 0.000 description 27
- 210000003470 mitochondria Anatomy 0.000 description 24
- 241000699666 Mus <mouse, genus> Species 0.000 description 21
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 18
- 230000035800 maturation Effects 0.000 description 17
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 210000001161 mammalian embryo Anatomy 0.000 description 15
- 238000002955 isolation Methods 0.000 description 14
- 239000010410 layer Substances 0.000 description 13
- 230000009261 transgenic effect Effects 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 11
- 210000004102 animal cell Anatomy 0.000 description 11
- 239000012894 fetal calf serum Substances 0.000 description 11
- 210000000056 organ Anatomy 0.000 description 11
- 230000002950 deficient Effects 0.000 description 10
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 230000002438 mitochondrial effect Effects 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 108020005196 Mitochondrial DNA Proteins 0.000 description 8
- 241001494479 Pecora Species 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 8
- 230000001605 fetal effect Effects 0.000 description 8
- 239000008188 pellet Substances 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 230000003466 anti-cipated effect Effects 0.000 description 7
- 230000000692 anti-sense effect Effects 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 7
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 7
- 241000283707 Capra Species 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000031864 metaphase Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 5
- 108090000994 Catalytic RNA Proteins 0.000 description 5
- 239000007995 HEPES buffer Substances 0.000 description 5
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 5
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 5
- 244000309466 calf Species 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 5
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000004602 germ cell Anatomy 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 241001550206 Colla Species 0.000 description 4
- 241000699800 Cricetinae Species 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 4
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 241000282887 Suidae Species 0.000 description 4
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 210000003754 fetus Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000012239 gene modification Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 230000005017 genetic modification Effects 0.000 description 4
- 235000013617 genetically modified food Nutrition 0.000 description 4
- 239000005090 green fluorescent protein Substances 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 244000144972 livestock Species 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 238000000520 microinjection Methods 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000002356 single layer Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 3
- 102000053642 Catalytic RNA Human genes 0.000 description 3
- 241000283086 Equidae Species 0.000 description 3
- 108010033040 Histones Proteins 0.000 description 3
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 description 3
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 3
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 3
- 238000011579 SCID mouse model Methods 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 3
- 210000001130 astrocyte Anatomy 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000029803 blastocyst development Effects 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 210000001771 cumulus cell Anatomy 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 230000017858 demethylation Effects 0.000 description 3
- 238000010520 demethylation reaction Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 239000011539 homogenization buffer Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000001459 mortal effect Effects 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 210000004508 polar body Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 108091092562 ribozyme Proteins 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- LAQPKDLYOBZWBT-NYLDSJSYSA-N (2s,4s,5r,6r)-5-acetamido-2-{[(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r)-5-acetamido-1,2-dihydroxy-6-oxo-4-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1r,2r)-1,2,3-trihydrox Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 LAQPKDLYOBZWBT-NYLDSJSYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 2
- MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 description 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 2
- 241000283726 Bison Species 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 2
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 101150051221 Dl gene Proteins 0.000 description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 102000008072 Lymphokines Human genes 0.000 description 2
- 108010074338 Lymphokines Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000711408 Murine respirovirus Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000283903 Ovis aries Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101150003725 TK gene Proteins 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- 206010043276 Teratoma Diseases 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 108090000848 Ubiquitin Proteins 0.000 description 2
- 102000044159 Ubiquitin Human genes 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229960002756 azacitidine Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 229940047120 colony stimulating factors Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000001085 differential centrifugation Methods 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 230000012173 estrus Effects 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- 229940028334 follicle stimulating hormone Drugs 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000002503 granulosa cell Anatomy 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000010874 in vitro model Methods 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000003098 myoblast Anatomy 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 208000000995 spontaneous abortion Diseases 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003104 tissue culture media Substances 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 2
- 229940045145 uridine Drugs 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- RDEIXVOBVLKYNT-HDZPSJEVSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-[(1r)-1-aminoethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2 Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)[C@@H](C)N)N)[C@@H](N)C[C@H]1N.O1[C@H]([C@@H](C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-HDZPSJEVSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 102100035656 BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 Human genes 0.000 description 1
- 101150035467 BDNF gene Proteins 0.000 description 1
- 102000051485 Bcl-2 family Human genes 0.000 description 1
- 108700038897 Bcl-2 family Proteins 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- 241001137251 Corvidae Species 0.000 description 1
- 102000002554 Cyclin A Human genes 0.000 description 1
- 108010068192 Cyclin A Proteins 0.000 description 1
- 102000003909 Cyclin E Human genes 0.000 description 1
- 108090000257 Cyclin E Proteins 0.000 description 1
- 102000002495 Cyclin H Human genes 0.000 description 1
- 108010068237 Cyclin H Proteins 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 229940122964 Deacetylase inhibitor Drugs 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 230000004668 G2/M phase Effects 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 101150092640 HES1 gene Proteins 0.000 description 1
- 102100034523 Histone H4 Human genes 0.000 description 1
- 102000003964 Histone deacetylase Human genes 0.000 description 1
- 108090000353 Histone deacetylase Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108700005087 Homeobox Genes Proteins 0.000 description 1
- 101000803294 Homo sapiens BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 Proteins 0.000 description 1
- 101000572981 Homo sapiens POU domain, class 3, transcription factor 1 Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical group C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 101100284799 Mus musculus Hesx1 gene Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 208000001738 Nervous System Trauma Diseases 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 102100021543 Solute carrier family 22 member 16 Human genes 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 229930189037 Trapoxin Natural products 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 210000002718 aborted fetus Anatomy 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003409 anti-rejection Effects 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 108700041737 bcl-2 Genes Proteins 0.000 description 1
- 230000006736 behavioral deficit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 210000001109 blastomere Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000032459 dedifferentiation Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000008143 early embryonic development Effects 0.000 description 1
- 210000001705 ectoderm cell Anatomy 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002242 embryoid body Anatomy 0.000 description 1
- 210000004039 endoderm cell Anatomy 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000000799 fusogenic effect Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 229940094892 gonadotropins Drugs 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 244000309465 heifer Species 0.000 description 1
- 230000006195 histone acetylation Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000002555 ionophore Substances 0.000 description 1
- 230000000236 ionophoric effect Effects 0.000 description 1
- 229940116871 l-lactate Drugs 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000001704 mesoblast Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 208000028412 nervous system injury Diseases 0.000 description 1
- 230000003988 neural development Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000002394 ovarian follicle Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008775 paternal effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000007908 penetration of oocytes Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 235000015108 pies Nutrition 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000031877 prophase Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000012090 serum-supplement Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 108010060597 trapoxin A Proteins 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2517/00—Cells related to new breeds of animals
- C12N2517/04—Cells produced using nuclear transfer
Definitions
- the present invention generally relates to the production of embryonic or
- the present invention more specifically relates to the production of primate or
- oocyte e.g., a primate or ungulate oocyte
- bovine enucleated oocyte in a preferred embodiment a bovine enucleated oocyte.
- the present invention further relates to the use of the resultant embryonic
- stem-like cells preferably primate or human embryonic or stem-like cells for
- transgenic embryonic or transgenic differentiated cells which may also be used for therapy or diagnosis, and for the production of transgenic embryonic or transgenic differentiated cells, cell lines, tissues and
- invention may themselves be used as nuclear donors in nuclear transplantation or
- transgenic cloned or chimeric animals transgenic cloned or chimeric animals.
- preimplantation mouse embryos are well known. (See, e.g., Evans et al., Nature,
- ES cells can be passaged in an undifferentiated state, provided that a feeder layer
- ES cells can be used as an in vitro model
- livestock animals e.g., ungulates, nuclei from like preimplantation livestock
- livestock animals are highly desirable because they may provide a potential source
- the reference disclosed culturing of
- ICM cells as donor nuclei in nuclear transfer procedures, to produce blastocysts
- the inner cell mass cells from NT units could be used to form an ES cell-like
- Collas et al taught the use of granulosa cells (adult somatic
- alkaline phosphatase activity are pluripotent, and have karyotypes which include
- SCID mouse Also, purported embryonic stem cell lines derived from human or
- Parkinson's disease is caused by
- Parkinson's which promises to have broad applicability to treatment of many brain
- Fetal neurons from a fetal or neonatal animals into the adult brain. Fetal neurons from a fetal or neonatal animals into the adult brain. Fetal neurons from a fetal or neonatal animals into the adult brain. Fetal neurons from a fetal or neonatal animals into the adult brain. Fetal neurons from a fetal or neonatal animals into the adult brain. Fetal neurons from a fetal or neonatal animals into the adult brain. Fetal neurons from a fetal or neonatal animals into the adult brain. Fetal neurons from a fetal or neonatal animals into the adult brain. Fetal neurons from a fetal or neonatal animals into the adult brain. Fetal neurons from a fetal or neonatal animals into the adult brain. Fetal neurons from a fetal or neonatal animals into the adult brain. Fetal neurons from a fetal or neonatal animals into the adult brain. Fetal neurons from a fetal or neonatal animals into the adult brain. Fetal neurons from a
- tissue obtained from miscarriages is very limited. Moreover, obtaining cells or
- stem-like undifferentiated cells for use in transplants and cell and gene thera-
- nucleus of a mammalian or human cell into an enucleated oocyte of a different
- a non-human primate or human cell involves transplantation of the nucleus of a non-human primate or human cell into an enucleated animal or human oocyte, e.g., an ungulate, human or primate
- human somatic cell (karyoplast) with an activated or non-activated, enucleated or
- non-enucleated oocyte of a different species e.g., bovine
- a different species e.g., bovine
- activated or unactivated cross-species NT unit which may be cleaved or uncleaved.
- human cell e.g., a human adult cell into an enucleated non-human primate or
- human oocyte wherein such cell has been genetically engineered to be incapable
- genes of the MHC I family e.g., genes of the MHC I family, and in particular Ped genes such
- antisense DNA encoding a cell death gene such as BAX, Apaf-1, or capsase, or a
- apoptosis e.g., by introduction of a DNA construct that provides for the
- genes that inhibit apoptosis e.g., Bcl-2 or Bcl-2 family members
- a visualizable (e.g., fluorescent tag) marker protein encodes a visualizable (e.g., fluorescent tag) marker protein.
- protease inhibitors preferably one or more capsase inhibitors, thereby inhibiting
- primate or human cell into an enucleated animal oocyte e.g., a human, primate or
- tissue or organ transplantation is therapeutically or diagnostically beneficial.
- transplantation therapy comprising the usage of isogenic or synegenic cells
- Such therapies include by way of example treatment
- transgenic animals e.g., non-human primates, rodents, ungulates, etc.
- transgenic animals can be
- polypeptides e.g., therapeutics or nutripharmaceuticals.
- Figure 1 is a photograph of a nuclear transfer (NT) unit produced by
- FIGS. 2 to 5 are photographs of embryonic stem-like cells derived from
- NT unit such as is depicted in Figure 1.
- the present invention provides a novel method for producing embryonic
- species or more specifically adult cells or DNA of one species (e.g., human) and
- stem-like cells and cell colonies may be obtained by transplantation of the nu-
- cleus of a human cell e.g., an adult differentiated human cell, into an enucleated
- animal oocyte which is used to produce nuclear transfer (NT) units, the cells of
- animal or human cell e.g., adult cell, into the enucleated egg of a different animal
- the NT units used to produce ES-like cells will be cultured to
- embryonic or stem-like cells refer to cells
- stem-like cells rather than stem cells because of the manner in which they are typically produced, i.e., by cross-species nuclear transfer. While these
- these stem-like cells may possess the mitochondria of the
- epithelial cell obtained from the oral cavity of a human donor, when transferred
- oocytes in general comprise factors
- RNAs and/or RNA sequences may comprise material RNAs and/or DNA sequences.
- bovine oocytes it is reasonable to expect that human cells may be transplanted into
- oocytes of other non-related species e.g., other ungulates as well as other animals.
- ungulate oocytes should be suitable, e.g. pigs, sheep, horses,
- oocytes from other sources should be suitable, e.g. oocytes
- the present invention involves the
- an oocyte (preferably enucleated) of an animal species different from the donor
- nuclei by injection or fusion, to produce an NT unit containing cells which may
- the invention may involve the transplantation of an
- nuclei are combined to produce NT units and which are cultured under conditions suitable to obtain multicellular NT units, preferably comprising at least about 2 to
- 400 cells more preferably 4 to 128 cells, and most preferably at least about 50
- the cells of such NT units may be used to produce embryonic or stem-like cells.
- the preferred embodiment of the invention comprises the
- enucleated human, primate, or non-primate animal oocyte e.g., an ungulate
- oocyte and in a preferred embodiment a bovine enucleated oocyte.
- the embryonic or stem-like cells will be produced by a nuclear radical
- oocytes obtained from a suitable source, e.g. a mammal and most
- a primate or an ungulate source e.g. bovine
- oocyte of an animal species different than the donor cell or nuclei e.g., by fusion
- steps (iii) and (iv) may be effected in either order;
- embryonic structures embryoid structures having a discernible inner cell mass
- Nuclear transfer techniques or nuclear transplantation techniques are examples of nuclear transfer techniques.
- Human or animal cells preferably mammalian cells, may be obtained and
- inventions include, by way of example, epithelial, neural cells, epidermal cells,
- keratinocytes hematopoietic cells, melanocytes, chondrocytes, lymphocytes
- T lymphocytes other immune cells, erythrocytes, macrophages, melanocytes,
- monocytes monocytes, mononuclear cells, fibroblasts, cardiac muscle cells, and other muscle
- the human cells used for nuclear transfer may be obtained.
- organs e.g., skin, lung, pancreas, liver, stomach, intestine, heart,
- Suitable donor cells i.e., cells useful in the subject invention, may be obtained from any cell or organ of the body. This
- the donor cells or nucleus would include all somatic or germ cells.
- the donor cells or nucleus would include all somatic or germ cells.
- the donor cells or nucleus would include all somatic or germ cells.
- the donor cells or nucleus would include all somatic or germ cells.
- such donor cells will be in the Gl cell
- the resultant blastocysts may be used to obtain embryonic stem cell lines
- epithelial cells were epithelial cells derived from the oral cavity of a human donor and adult
- cell nuclei may be obtained from
- Zygote gene activation is associated with hyperacetylation of Histone H4.
- Trichostatin-A has been shown to inhibit histone deacetylase in a reversible
- Trichostatin A and trapoxin novel chemical probes for the
- deacetylase Generally, butyrate appears to modify gene expression and in almost
- donor cells may be exposed to Trichostatin-A or
- azacytidine can be used to reduce the level of DNA methylation in cells
- donor cells may be exposed to 5-azacytidine (5-Aza)
- the oocytes used for nuclear transfer may be obtained from animals
- Suitable mammalian sources for oocytes including mammals and amphibians. Suitable mammalian sources for oocytes
- mice include sheep, bovines, ovines, pigs, horses, rabbits, goats, guinea pigs, mice,
- the oocytes are hamsters, rats, primates, humans, etc.
- the oocytes are hamsters, rats, primates, humans, etc.
- the oocytes are hamsters, rats, primates, humans, etc.
- primates or ungulates e.g., a bovine.
- oocytes from the ovaries or reproductive tract of a mammal
- bovine oocytes e.g., bovine oocytes
- oocytes must generally be matured in vitro before these cells
- recipient cells may be used as recipient cells for nuclear transfer, and before they can be fertilized
- immature (prophase I) oocytes from animal ovaries, e.g., bovine ovaries obtained at a slaughterhouse and maturing the oocytes in a maturation medium
- bovine oocytes generally occurs about 18-24 hours post-
- this period of time is known as
- tion refers to aspiration of the immature oocyte from ovarian follicles.
- metaphase II stage oocytes which have been matured in vivo
- metaphase II oocytes are collected surgically from either non- superovulated or
- hCG human chorionic gonadotropin
- the recipient oocyte because at this stage it is believed that the oocyte can be or is
- the oocyte activation period In domestic animals, and especially cattle, the oocyte activation period
- immature oocytes may be washed in HEPES buffered hamster
- HECM embryo culture medium
- TCM tissue culture medium
- FSH follicle stimulating hormone
- the oocytes will typically be
- the oocytes Prior to enucleation the oocytes will preferably be removed and
- enucleation may be effected before or after introduction of donor
- Enucleation may be effected by known methods, such as described in U.S.
- Patent No. 4,994,384 which is incorporated by reference herein.
- metaphase II oocytes are either placed in HECM, optionally containing 7.5 micrograms per milliliter cytochalasin B, for immediate enucleation, or may be
- a suitable medium for example CRlaa, plus 10% estrus cow serum, and
- Enucleation may be accomplished microsurgically using a micropipette to
- the oocytes may then be
- screening may be effected by staining the oocytes with 1 microgram per milliliter
- enucleated can then be placed in a suitable culture medium.
- the recipient oocytes will typically be enucleated
- vitro maturation more preferably from about 16 hours to about 24 hours after
- Enucleation may be effected before, simultaneous or
- enucleation may be effected before, after or
- perivitelline space of the oocyte typically enucleated, used to produce the NT unit.
- removal of endogenous nucleus may alternatively be effected after
- the cells may be fused by electrofusion. Electrofusion is accomplished
- electrofusion media can be used including e.g., sucrose, mannitol, sorbitol and
- Fusion can also be accomplished using Sendai virus
- the human or animal cell and oocyte are electrofused in a 500 .
- fused NT units are preferably placed in a suitable medium until activation, e.g.,
- activation may be effected from about twelve hours prior to nuclear
- activation is effected simultaneous or shortly after nuclear transfer, e.g., about four
- the NT unit may be activated by known methods. Such methods include,
- activation may be achieved by application of known
- activation agents For example, penetration of oocytes by sperm during
- Suitable oocytes may transfer treatments such as electrical and chemical shock or cycloheximide treatment. Also, treatments such as electrical and chemical shock or cycloheximide treatment may also be used to activate NT embryos after fusion. Suitable oocytes
- oocyte activation may be effected by simultaneously or
- oocyte cytoplasm e.g., magnesium, strontium, barium or calcium, e.g., in the form
- Phosphorylation may be reduced by known methods, e.g., by the addition
- kinase inhibitors e.g., serine-threonine kinase inhibitors, such as 6-dimethyl-
- phosphorylation of cellular proteins may be inhibited by
- a phosphatase into the oocyte, e.g., phosphatase 2A and
- mice mice, rats, rabbits or hamsters
- transfer procedures e.g., those including the use of primate or human donor cells
- both the donor cell and nucleus is of ungulate origin, e.g., a sheep, buffalo, horse,
- oocyte is of ungulate origin, e.g., sheet, pig,
- activation may be effected before, simultaneous, or after nuclear
- oocyte e.g., approximately simultaneous or within about 40 hours of maturation
- Activated NT units may be cultured in a suitable in vitro culture medium
- FCS fetal calf serum
- TCM-199 Medium- 199 + 10% fetal calf serum, Tyrodes-Albumin-Lactate- Pyruvate (TALP), Dulbecco's Phosphate Buffered Saline (PBS), Eagle's and
- TCM-199 maturation of oocytes is TCM-199, and 1 to 20% serum supplement including fetal
- preferred maintenance medium includes TCM-199 with Earl salts, 10% fetal calf
- human epithelial cells of the endometrium secrete leukemia
- LIF inhibitory factor
- CR1 contains the nutritional substances necessary to support an
- CR1 contains hemicalcium L-lactate in amounts ranging from 1.0 mM
- Hemicalcium L-lactate is L-lactate with
- hemicalcium salt incorporated thereon.
- the cultured NT unit or units are preferably washed and then
- a suitable media e.g., CRIaa medium, Ham's F-10, Tissue Culture Media
- TCM-199 Tyrodes-Albumin-Lactate-Pyruvate (TALP) Dulbecco's
- PBS Phosphate Buffered Saline
- Eagle's or Whitten's preferably containing
- Suitable feeder layers include, by way
- fibroblasts and epithelial cells e.g., fibroblasts and uterine epithelial cells
- the feeder cells will comprise mouse
- the NT units are cultured on the feeder layer until the NT units reach a size
- these NT units will be cultured until they reach
- Another preferred medium comprises ACM + uridine + glucose + 1000 IU
- the cells used in the present invention will preferably comprise mammalian somatic cells, most preferably cells derived from
- the donor cell will be genetically modified by the addition,
- the donor cell For example, the donor cell, the donor cell, the donor cell, and
- a keratinocyte or fibroblast e.g., of human, primate or bovine origin, may be
- a desired gene product e.g., therapeutic polypeptide.
- a desired gene product e.g., therapeutic polypeptide.
- therapeutic polypeptide examples thereof include
- lymphokines e.g., IGF-I, IGF-II, interferons, colony stimulating factors,
- connective tissue polypeptides such as collagens, genetic factors, clotting factors,
- the donor cells may be modified prior to nuclear
- One aspect of the invention will involve genetic modification of the donor
- a human cell e.g., a human cell, such that it is lineage deficient and therefore when used for
- cells may be genetically modified such that when used as nuclear
- Examples thereof include:
- Endoderm GATA-6, GATA-4;
- Ectoderm RNA helicase A, H beta 58.
- a desired somatic cell e.g., a human keratinocyte, epithelial cell
- fibroblast will be genetically engineered such that one or more genes specific
- This genetically modified cell will be used to produce a lineage-defective
- nuclear transfer embryo i.e., that does not develop at least one of a functional
- lineage deficient donor cells may also be genetically modified to
- the genetically modified donor cell will give rise to a lineage-
- the donor cell can be modified such that it is “mortal”. This
- telomere telomerase genes can be achieved by expressing anti-sense or ribozyme telomerase genes. This can be achieved by expressing anti-sense or ribozyme telomerase genes. This can be achieved by expressing anti-sense or ribozyme telomerase genes. This can be achieved by expressing anti-sense or ribozyme telomerase genes. This can be achieved by expressing anti-sense or ribozyme telomerase genes. This can be achieved by expressing anti-sense or ribozyme telomerase genes. This can be achieved by expressing anti-sense or ribozyme telomerase genes. This can be achieved by expressing anti-sense or ribozyme telomerase genes. This can be achieved by expressing anti-sense or ribozyme telomerase genes. This can be achieved by expressing anti-sense or ribozyme telomerase genes. This can be achieved by expressing anti-sense or ribozy
- blastocysts and ES cells resulting from nuclear transfer may have impaired
- expression construct can be constructed containing a strong constitutive
- Suitable selectable markers e.g,. neomycin, ADA, DHFR, and a poly-A
- sequence e.g., bGH polyA sequence. Also, it may be advantageous to further
- genes are highly conserved in different species, e.g., bovines, goats, porcine, dogs,
- donor cells can be engineered to affect other genes that enhance embryonic development.
- modified donor cells should produce blastocysts and preimplantation stage
- Still another aspect of the invention involves the construction of donor cells
- apoptosis examples include, e.g., Bad, Bok, BH3, Bik, Hrk, BNIP3, Bim L , Bad,
- cell death include, by way of example, BcL-XL, Bcl-w, Mcl-l, Al, Nr-13, BHRF-
- donor cells can be constructed wherein genes that induce apoptosis
- apoptosis is enhanced or turned on during embryonic development.
- this can be effected by introducing a DNA construct that
- a DNA construct containing a Bcl-2 gene operably
- a regulatable or constitutive promoter e.g., PGK, SV40, CMV, ubiquitin, or beta-actin, an IRES, a suitable selectable marker, and a poly-A sequence
- a transgene may be
- donor cells may be constructed containing
- Another means of enhancing cloning efficiency is to select cells of a
- a particular cyclin DNA may be operably linked to a regulatory
- GFP green fluorescent protein
- An example thereof is the cyclin Dl gene in order to select for cells that
- Cyclins are proteins that are expressed only during specific stages of the
- donor cells will be constructed that express one or
- cyclin DNA may be operably linked to a regulatory sequence, together with a
- detectable marker e.g., green fluorescent protein (GFP)
- GFP green fluorescent protein
- destruction box and optionally insulation sequences to enhance cyclin and/or
- cyclin Dl gene which can be used to select for cells that are in Gl.
- any cyclin gene should be suitable for use in the claimed invention.
- proteases such as capsases
- capsase-4 inhibitor I examples include by way of example capsase-4 inhibitor I, capsase-3 inhibitor I, capsase-6
- NT unit typically will contain at least about 50 cells
- a feeder layer e.g., irradiated fibroblast cells.
- the cells used to obtain the stem-like cells or cell colonies will be
- NT units of smaller or greater cell numbers as
- oocyte's cytosol may facilitate the dedifferentiation process. This can be
- cell may be fused with an enucleated oocyte and four to six hours later, without
- the cells are maintained in the feeder layer in a suitable growth medium
- alpha MEM e.g., alpha MEM supplemented with 10% FCS and 0.1 mM beta-mercaptoethanol (Sigma) and L-glutamine.
- FCS fetal calf serum
- beta-mercaptoethanol Sigma
- L-glutamine L-glutamine
- the embryonic or stem-like cells and cell colonies obtained will typically be obtained.
- the nuclear cell donor rather than the species of the donor oocyte.
- the nuclear cell donor rather than the species of the donor oocyte.
- nuclear donor cell into an enucleated bovine oocyte the cells exhibit a morphology
- bovine ES-like cells more similar to mouse embryonic stem cells than bovine ES-like cells.
- the individual cells of the human ES-line cell colony are the individual cells of the human ES-line cell colony.
- the cell colony has a longer cell doubling time, about twice
- mouse ES cells that of mouse ES cells. Also, unlike bovine and porcine derived ES cells, the
- primate ES cells produced according to the present methods will exhibit similar characteristics
- inventions are pluripotent will be confirmed by injecting such cells into an animal,
- tissue samples e.g., a SCID mouse, or large agricultural animal, and thereafter obtaining tissues
- mesoderm i.e., mesoderm, ectoderm
- differentiated tissues i.e., mesoderm, ectoderm
- the resultant embryonic or stem-like cells and cell lines preferably human
- embryonic or stem-like cells and cell lines have numerous therapeutic and
- embryonic or stem-like cells may be used as diagnostic applications. Most especially, such embryonic or stem-like cells.
- Still another object of the present invention is to improve the efficacy of
- nuclear transfer e.g., cross-species nuclear transfer by introducing mitochondrial
- the donor cell is human, human mitochondrial
- DNA will be derived from cells of the particular donor, e.g., liver cells and tissue.
- Mitochondria can be isolated from cells in tissue culture, or from tissue.
- Examples of cells or tissues that may be used as sources of mitochondria include
- fibroblasts epithelium, liver, lung, keratinocyte, stomach, heart, bladder, pancreas,
- lymphocytes esophageal, lymphocytes, monocytes, mononuclear cells, cumulus cells, uterine
- mitochondria can be isolated from tissue culture cells and rat
- mitochondria comprises human liver tissue because such cells contain a large
- the isolated DNA can also be further purified, if desired, known methods, e.g., density
- mouse embryonic stem (ES) cells are known that mouse embryonic stem (ES) cells are known.
- hematopoietic stem cells capable of differentiating into almost any cell type, e.g., hematopoietic stem cells.
- the embryonic or stem ⁇ should possess similar differentiation capacity.
- the embryonic or stem ⁇ should possess similar differentiation capacity.
- the subject human has a desired cell types according to known methods.
- the subject human has a desired cell types according to known methods.
- the subject human has a desired cell types according to known methods.
- the subject human has a desired cell types according to known methods.
- the subject human has a desired cell types according to known methods.
- the subject human has a desired cell types according to known methods.
- the subject human has a desired cell types according to known methods.
- embryonic or stem-like cells may be induced to differentiate into hematopoietic
- stem cells muscle cells, cardiac muscle cells, liver cells, cartilage cells, epithelial cells
- hematopoietic cells including hematopoietic cells, muscle, cardiac muscle, nerve cells, among others.
- embryonic stem cells are incorporated by reference in their entirety herein.
- neural cells e.g., neural cells, muscle cells, hematopoietic cells, etc.
- muscle cells e.g., hematopoietic cells, etc.
- hematopoietic cells e.g., neural cells, muscle cells, hematopoietic cells, etc.
- inducible Bcl-2 or Bcl-xl might be useful for enhancing in vitro development
- Bcl-2 prevents many, but not all, forms of
- the subject embryonic or stem-like cells may be used to obtain any desired
- differentiated cell type therapeutic usages of such differentiated human cells are unparalleled.
- human hematopoietic stem cells may be used in
- Hematopoietic stem cells can be obtained, e.g., by fusing adult somatic cells of
- a cancer or AIDS patient e.g., epithelial cells or lymphocytes with an enucleated
- oocyte e.g., bovine oocyte
- embryonic or stem-like cells as described
- hematopoietic stem cells are obtained. Such hematopoietic cells may be used in
- disorder may be fused with an enucleated animal oocyte, e.g., a primate or bovine
- oocyte human embryonic or stem-like cells obtained therefrom, and such cells
- Parkinson's disease Alzheimer's disease
- ALS cerebral palsy
- donor cells may be any suitable differentiated cells.
- donor cells may be any suitable differentiated cells.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Psychology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Developmental Biology & Embryology (AREA)
- Communicable Diseases (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA02002744A MXPA02002744A (en) | 1999-09-14 | 2000-09-14 | Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions. |
AU77019/00A AU7701900A (en) | 1999-09-14 | 2000-09-14 | Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions |
JP2001523749A JP2003525031A (en) | 1999-09-14 | 2000-09-14 | Method for enhancing embryo development by genetically modifying embryonic cells or stem-like cell lines and donor cells produced by hybrid nuclear transfer or tissue culture conditions |
CA002384413A CA2384413A1 (en) | 1999-09-14 | 2000-09-14 | Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions |
IL14854700A IL148547A0 (en) | 1999-09-14 | 2000-09-14 | Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions |
NZ517609A NZ517609A (en) | 1999-09-14 | 2000-09-14 | Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions |
BR0013999-8A BR0013999A (en) | 1999-09-14 | 2000-09-14 | Embryonic or stem cell-like cell lines produced by cross-species nuclear transplantation and methods to improve embryonic development by genetic alteration of donor cells or by tissue culture conditions |
EP00966717A EP1214404A4 (en) | 1999-09-14 | 2000-09-14 | Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions |
IL148547A IL148547A (en) | 1999-09-14 | 2002-03-06 | Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39536899A | 1999-09-14 | 1999-09-14 | |
US09/395,368 | 1999-09-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001019977A1 WO2001019977A1 (en) | 2001-03-22 |
WO2001019977A9 true WO2001019977A9 (en) | 2002-09-26 |
Family
ID=23562752
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/025090 WO2001019977A1 (en) | 1999-09-14 | 2000-09-14 | Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1214404A4 (en) |
JP (1) | JP2003525031A (en) |
CN (1) | CN1379814A (en) |
AU (1) | AU7701900A (en) |
BR (1) | BR0013999A (en) |
CA (1) | CA2384413A1 (en) |
IL (2) | IL148547A0 (en) |
MX (1) | MXPA02002744A (en) |
NZ (1) | NZ517609A (en) |
WO (1) | WO2001019977A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7696404B2 (en) | 1996-08-19 | 2010-04-13 | Advanced Cell Technology, Inc. | Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions |
WO2001018193A1 (en) * | 1999-09-07 | 2001-03-15 | Advanced Cell Technology, Inc. | Method for generating immune-compatible cells and tissues using nuclear transfer techniques |
CN1413250A (en) * | 1999-10-15 | 2003-04-23 | 先进细胞技术公司 | Method of producing differentiated progenitor cells and lineage-defective embryonic stem cells |
CN1425064A (en) * | 1999-12-20 | 2003-06-18 | 马萨诸塞大学 | Embryonic or stem-like cells produced by cross species nuclear transplantation |
US10865383B2 (en) | 2011-07-12 | 2020-12-15 | Lineage Cell Therapeutics, Inc. | Methods and formulations for orthopedic cell therapy |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5843780A (en) * | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
EP0934403A4 (en) * | 1996-08-19 | 2001-03-14 | Univ Massachusetts | Embryonic or stem-like cell lines produced by cross species nuclear transplantation |
AU8587598A (en) * | 1997-07-26 | 1999-02-16 | Wisconsin Alumni Research Foundation | Trans-species nuclear transfer |
AU759322B2 (en) * | 1998-03-02 | 2003-04-10 | University Of Massachusetts | Embryonic or stem-like cell lines produced by cross-species nuclear transplantation |
CN1425064A (en) * | 1999-12-20 | 2003-06-18 | 马萨诸塞大学 | Embryonic or stem-like cells produced by cross species nuclear transplantation |
-
2000
- 2000-09-14 MX MXPA02002744A patent/MXPA02002744A/en not_active Application Discontinuation
- 2000-09-14 EP EP00966717A patent/EP1214404A4/en not_active Withdrawn
- 2000-09-14 NZ NZ517609A patent/NZ517609A/en unknown
- 2000-09-14 CN CN00814278A patent/CN1379814A/en active Pending
- 2000-09-14 JP JP2001523749A patent/JP2003525031A/en active Pending
- 2000-09-14 AU AU77019/00A patent/AU7701900A/en not_active Abandoned
- 2000-09-14 BR BR0013999-8A patent/BR0013999A/en not_active Application Discontinuation
- 2000-09-14 WO PCT/US2000/025090 patent/WO2001019977A1/en active IP Right Grant
- 2000-09-14 CA CA002384413A patent/CA2384413A1/en not_active Abandoned
- 2000-09-14 IL IL14854700A patent/IL148547A0/en unknown
-
2002
- 2002-03-06 IL IL148547A patent/IL148547A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
BR0013999A (en) | 2002-05-21 |
EP1214404A4 (en) | 2003-09-03 |
JP2003525031A (en) | 2003-08-26 |
MXPA02002744A (en) | 2003-07-21 |
CA2384413A1 (en) | 2001-03-22 |
AU7701900A (en) | 2001-04-17 |
WO2001019977A1 (en) | 2001-03-22 |
EP1214404A1 (en) | 2002-06-19 |
IL148547A (en) | 2009-09-01 |
CN1379814A (en) | 2002-11-13 |
IL148547A0 (en) | 2002-09-12 |
NZ517609A (en) | 2004-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU740709B2 (en) | Embryonic or stem-like cell lines produced by cross species nuclear transplanta tion | |
AU742363B2 (en) | Nuclear transfer with differentiated fetal and adult donor cells | |
US20010012513A1 (en) | Embryonic or stem-like cell lines produced by cross species nuclear transplantation | |
EP1159404A2 (en) | Embryonic or stem-like cell lines produced by cross species nuclear transplantation | |
US7696404B2 (en) | Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions | |
NZ502129A (en) | Cloning using donor nuclei from non-serum starved, differentiated cells | |
AU784731B2 (en) | Embryonic or stem-like cells produced by cross species nuclear transplantation | |
AU759322B2 (en) | Embryonic or stem-like cell lines produced by cross-species nuclear transplantation | |
AU2008229989A1 (en) | Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions | |
WO2001019977A9 (en) | Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions | |
US20050095704A1 (en) | Embryonic or stem-like cell lines produced by cross species nuclear transplantation | |
AU2005225103A1 (en) | Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions | |
AU2006201208A1 (en) | Embryonic or stem-like cells produced by cross species nuclear transpantation | |
MXPA00008602A (en) | Embryonic or stem-like cell lines produced by cross-species nuclear transplantation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 517609 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 148547 Country of ref document: IL Ref document number: 77019/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2384413 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/002744 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2001 523749 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000966717 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 008142785 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2000966717 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10070719 Country of ref document: US |
|
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1-67, DESCRIPTION, REPLACED BY NEW PAGES 1-72; PAGES 68-75, CLAIMS, REPLACED BY NEW PAGES 73-81; PAGES 1/3-3/3, DRAWINGS, REPLACED BY NEW PAGES 1/3-3/3; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
WWP | Wipo information: published in national office |
Ref document number: 517609 Country of ref document: NZ |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000966717 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 517609 Country of ref document: NZ |